Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04056910
Title Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jason J. Luke, MD
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST